Discovery of novel antibiotics
Product or Service High throughput screening and lead discovery
A large network of 17 experienced screening centres, including two institutes with focus on infectious diseases.
- Antimicrobial compound/strategy
- License, Co-develop, Joint Venture
- OTHER / NA
Infectious disease area:
Embargo period of up to three years before screening data become open access. EU-OPENSCREEN works with full cost model and claims no IPR.
European research infrastructure consortium (ERIC) for chemical biology
Access to commercial and proprietary compound collections, medicinal chemistry expertise at 6 sites. Co-development of novel screening technologies.